We are now working in personalized medicine. We've got an oncology group that is made up of diagnostics people and pharmaceutical people, and they are looking at biomarkers and genetic markers of patients who were given drugs. So, we're going to be able to determine who is a responder and who is n...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
